7%). HIV positivity was defined as positive results for both tests. The test result was recorded on the study CRF. Participants with a positive result were offered
medical follow-up at the Manhiça out-patient clinic, which included CD4 cell counts, clinical management and provision of ARV treatment if needed, following national guidelines. In addition to the population-based study, data from the routine HIV screening of pregnant women attending the ANC of the MDH were collected prospectively from March to September 2010. Data from the study CRFs were double-entered at the CISM using the OpenClinica software for clinical data management (www.openclinica.org). The statistical analysis was performed using stata software version 11 (Stata Corp., College Station, TX). One-way and two-way contingency tables were generated for description of the categorical variables and calculation of proportions and P-values. The probability Trametinib mouse of sampling was taken into account to extrapolate the data from the survey to the community
by weighting the sample groups (defined by sex and age) and using DSS data [18]. A total of 1124 adults were approached to determine their availability to participate in the study and were given an appointment card for a later mobile team visit. Of those who made an appointment, 839 adults (74.6%) met with the mobile team, received the study information Vemurafenib clinical trial and were invited to participate in the study. Reasons for not receiving the study information were refusal (3.7%), absent twice at the second household visit (8.1%), not eligible (10.3%), and unknown (3.3%). Of the 839 adults invited to participate, 722 agreed to participate and were recruited (acceptance rate 86.1%). Almost 60% (68 of 117) of the individuals who did not agree to participate in the study were men. This sex difference in the acceptance rate was statistically significant only in the 28–37-year-old group (P = 0.016).
Table 1 shows the acceptance rate by sex and age Avelestat (AZD9668) group. Twenty-seven out of 117 individuals (23%) who did not participate in the study claimed that they already knew their HIV status. Almost half of the participants (45.1%) were unemployed. Their sociodemographic characteristics are shown in Table 2. The overall HIV prevalence was 39.9% (95% CI 35.9–43.8%). Four (0.6%) out of 722 tested individuals had an indeterminate HIV test result. Young adults (18–27 years) had the lowest HIV prevalence rates (23.2%; 95% CI 17.9–28.6%). The HIV prevalence in older adults (28–47 years) was found to be significantly higher than in younger individuals (P < 0.0001). The overall proportion of HIV-infected individuals tended to be higher among women (43.1%; 95% CI 37.6–48.5%) than men (37.6%; 95% CI 33.0–43.2%) but this difference between sexes was not statistically significant (P = 0.33) (Table 3).